Mersana Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €406.96M +292.3% €212.94M -679.5% 52.3% +0.88 pp N/A N/A
    (estimated) €103.73M +744.5% -€36.75M -61.9% -35.4% +7.5 pp N/A N/A
    (estimated) €12.28M +∞% -€96.56M +28.8% -786.2% -7.9 pp N/A N/A
    (estimated) N/A -€74.97M +10.1% N/A N/A N/A
    (estimated) N/A -€68.11M +15.4% N/A N/A N/A
    €34.54M +9.9% -€59.02M -59.7% -170.9% +2.9 pp -€70.12M -50.7% -203.0% +2.5 pp
    €31.44M +38.7% -€146.43M -17.3% -465.8% +3.1 pp -€142.20M +253.5% -452.4% -2.7 pp
    €22.67M +61,716.3% -€177.02M +22.7% -780.8% +3.9K pp -€40.23M -66.2% -177.4% +3.2K pp
    €36.68K -94.8% -€144.32M +91.4% -393,500.0% -3.8K pp -€118.85M +87.7% -324,046.5% -3.2K pp
    €706.24K -98.0% -€75.40M +225.1% -10,676.8% -110 pp -€63.31M +10.6% -8,964.1% -88 pp
    €35.93M +297.6% -€23.20M -57.7% -64.6% +5.4 pp -€57.27M +24.7% -159.4% +3.5 pp
    €9.04M -39.6% -€54.81M +66.0% -606.5% -3.9 pp -€45.93M +29.6% -508.3% -2.7 pp
    €14.97M -30.3% -€33.02M +182.5% -220.6% -1.7 pp -€35.43M -227.1% -236.7% -3.7 pp
    €21.47M +143.0% -€11.69M -16.6% -54.4% +1.0 pp €27.87M -462.3% 129.8% +2.2 pp
    €8.84M -€14.01M -158.6% -€7.69M -87.0%

    Notifications